Expert Interview
A Second Opinion: Discussing the potential of Pfizer's Marstacimab for the treatment of hemophilia A and B
Ticker(s): PFEInstitution: The University of Texas Health Science Center at Houston
- Hematologist and Professor at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth).
- Currently manages over 500 patients with Hemophilia and familiar with the results from the Phase 3 BASIS clinical trial regarding Pfizer's Marstacimab for treatment of hemophilia A and B.
- Research interests include hemophilia and inhibitors, general hemostasis, thrombophilia and venous thromboembolism; has contributed extensively to the literature clinically and scientifically in numerous subjects concerning bleeding and clotting disorders.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
